KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) EBT Margin (2016 - 2025)

Historic EBT Margin for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to 46.87%.

  • Gilead Sciences' EBT Margin rose 342000.0% to 46.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.99%, marking a year-over-year increase of 333700.0%. This contributed to the annual value of 2.4% for FY2024, which is 229000.0% down from last year.
  • As of Q3 2025, Gilead Sciences' EBT Margin stood at 46.87%, which was up 342000.0% from 34.3% recorded in Q2 2025.
  • Gilead Sciences' EBT Margin's 5-year high stood at 46.87% during Q3 2025, with a 5-year trough of 67.1% in Q1 2024.
  • In the last 5 years, Gilead Sciences' EBT Margin had a median value of 27.49% in 2022 and averaged 21.86%.
  • Its EBT Margin has fluctuated over the past 5 years, first crashed by -875600bps in 2024, then soared by 918300bps in 2025.
  • Quarter analysis of 5 years shows Gilead Sciences' EBT Margin stood at 10.48% in 2021, then soared by 162bps to 27.49% in 2022, then fell by -15bps to 23.24% in 2023, then increased by 23bps to 28.63% in 2024, then surged by 64bps to 46.87% in 2025.
  • Its last three reported values are 46.87% in Q3 2025, 34.3% for Q2 2025, and 24.73% during Q1 2025.